Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YIL 781 is a selective ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM), showing a weak affinity for kinesin receptors (K = 6 μM). YIL 781 improves glucose homeostasis in vivo and in vitro by blocking ghrelin secretion.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 155.00 | |
25 mg | In stock | $ 328.00 | |
50 mg | In stock | $ 493.00 | |
100 mg | In stock | $ 689.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 125.00 |
Description | YIL 781 is a selective ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM), showing a weak affinity for kinesin receptors (K = 6 μM). YIL 781 improves glucose homeostasis in vivo and in vitro by blocking ghrelin secretion. |
In vitro | Post-transcriptional suppression by Ghsr siRNA transfection and treatment with GHS-R antagonist, YIL781, both significantly attenuated the effects of ghrelin in RGC-5 cells.[1] |
In vivo | YIL781 (ghrelin receptor antagonist; from 0.1 to 5 μg; i.t. pretreatment) markedly attenuated the ghrelin-induced hyperglycemic effect. The plasma insulin level was increased by ghrelin. The enhanced plasma insulin level by ghrelin was reduced by i.t. pretreatment with YIL781.[2] With YIL781 pretreatment, the accumulated radioactivity in the pancreas 15-60min after [11C]3 injection was significantly decreased to 78% of control.[3] |
Molecular Weight | 409.5 |
Formula | C24H28FN3O2 |
CAS No. | 875258-85-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40.1 mg/mL (90.0 mM)
H2O: 40.1 mg/mL (90.0 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YIL 781 875258-85-8 GPCR/G Protein GHSR YIL-781 YIL781 inhibitor inhibit